Nutex Health Inc. (NUTX)

Nutex Health Inc. operates in the healthcare services industry, specifically within the hospital services market, which is the largest single category of healthcare expenditures in the United States. According to the Centers for Medicare & Medicaid Services, national healthcare expenditures grew 7.2% in 2024 to $5.3 trillion, and hospital care expenditures increased 9.2% from the previous year to total about $1.7 trillion. CMS projects that the hospital services category will grow at an average of 5.5% annually from 2028 through 2033, reaching nearly $2.7 trillion by 2033. The U.S. hospital industry includes approximately 5,112 community hospitals, of which about 35% are located in non-urban communities. The healthcare industry is highly competitive and highly fragmented, with competition based on the nature and caliber of relationships with physicians, patient healthcare quality, outcomes and cost, the strength of relationships with payors, the quality of the physician experience, local geography leadership position, and the strength of the underlying economic model.

The company's primary competitors are free-standing emergency departments and traditional large local hospital systems that are developing micro-hospitals to increase their footprint in their local communities. Competitors typically vary by geography, and there are few financial barriers to entry as facilities and equipment may be leased. The company believes its business, partnership and operations model enables it to compete favorably. The company's competitive advantages include a patient-centric care model, a differentiated provider engagement and partnership strategy where physician partners are co-investors and in many instances stockholders of Nutex, and a scalable go-to-market strategy with centralized administrative support functions including billing and collection, purchasing, marketing, legal and compliance, human resources and financial operations.

The company generates revenue through two primary divisions: the hospital division and the population health management division. The hospital division receives payment for facility services rendered from federal agencies, private insurance carriers, and patients, with greater than 99% of net patient service revenue paid by insurers, federal agencies, and other non-patient third parties. The company generally operates as an out-of-network provider and does not have negotiated reimbursement rates with most insurance companies. The population health management division recognizes revenue for capitated payments and management fees for services to IPAs and physician groups monthly. Capitation revenue consists primarily of capitated fees for medical services provided by physician-owned entities the company consolidates as VIEs, where capitation is a fixed payment amount per patient per unit of time paid in advance for the delivery of health care services, with service providers generally liable for excess medical costs. Management fees are based on gross capitation revenues of the IPAs or physician groups managed.

The hospital division develops and operates a network of micro-hospitals, specialty hospitals and hospital outpatient departments providing comprehensive and high-quality 24/7 care. As of December 31, 2025, the company owned and operated 26 healthcare facilities across 12 states and had an additional nine de novo micro-hospitals under various stages of development. Most licensed micro-hospitals average approximately 15,000 to 25,000 square feet and include seven to eight emergency treatment rooms, two to ten in-patient beds for both short- and long-term stays and advanced imaging equipment, laboratory and pharmacy services. Staffing at each facility includes four to ten physicians and hospitalists depending on the community's needs. The hospital division generally operates as an out-of-network provider. For the year ended December 31, 2025, hospital division revenue was $844,162,000 ¹ compared to $449,064,000 ² in 2024 and $218,070,000 ³ in 2023. Hospital division operating income was $444,027,000 ⁴ in 2025 compared to $195,539,000 ⁵ in 2024 and $36,336,000 ⁶ in 2023.

The population health management division establishes and operates provider networks such as independent physician associations. Through its Management Services Organization, Nutex provides management, administrative, and other support services to its affiliated hospitals and physician groups. The company manages one IPA located in Los Angeles, California with over 230 primary care physicians, 2,800 specialists and ancillary providers and an enrollment of approximately 32,750 patients. The company has established three other IPAs in Houston, South Florida and Phoenix. As of the filing date, the Houston IPA has over 90 contracted PCPs, 320 specialists and manages over 1,900 Medicare Advantage patients. The South Florida IPA is contracted with approximately 90 PCPs and manages over 3,700 members, including over 250 MA patients. The Phoenix IPA is contracted with 19 PCPs and 60 specialists. In total, the company's IPAs have approximately 38,000 members across their platform, including commercial and Medicaid managed care members. For the year ended December 31, 2025, population health management division revenue was $31,095,000 ⁷ compared to $30,885,000 ⁸ in 2024 and $29,576,000 ⁹ in 2023. The division had operating income of $690,000 ¹⁰ in 2025 compared to $1,380,000 ¹¹ in 2024 and an operating loss of $1,559,000 ¹² in 2023.

On May 2, 2025, the company acquired a 51% membership interest in an Indiana-based limited liability company for $2.3 million ¹³ in cash. On September 19, 2025, the company acquired certain assets and assumed specific liabilities of a non-operational hospital facility in St. Louis, Missouri, agreeing to a $5.8 million ¹⁴ seller note, real property and equipment lease obligations, a deferred payment of $1.0 million ¹⁵ over 10 years, and issuance of a 15% membership interest in the consolidated subsidiary over a two-year period. On December 17, 2025, the company acquired land and an office building for $2.2 million ¹⁶ in cash. On August 14, 2025, the Board authorized a stock repurchase program of up to $25.0 million ¹⁷ of the company's common stock over the subsequent six months. During the year ended December 31, 2025, the company repurchased 27,870 ¹⁸ shares of common stock under the Repurchase Program at a weighted-average price of $177.73 ¹⁹ for an aggregate purchase price of $5.0 million ²⁰. On October 31, 2025, remaining note holders of unsecured convertible term notes converted $4.9 million ²¹ of principal and $0.1 million ²² of interest to 165,030 ²³ shares of the company's common stock, valued at $30.00 ²⁴ per share. On December 16, 2025, a Holder completed a cashless exercise of a Warrant and the company issued 40,387 ²⁵ shares of its common stock.

Total revenue for the year ended December 31, 2025 was $875,257,000 ²⁶ compared to $479,949,000 ²⁷ in 2024 and $247,646,000 ²⁸ in 2023. Net income attributable to Nutex Health Inc. was $70,789,000 ²⁹ in 2025 compared to $52,097,000 ³⁰ in 2024 and a net loss of $45,787,000 ³¹ in 2023. Diluted earnings per share was $10.48 ³² in 2025 compared to $9.69 ³³ in 2024 and a loss of $10.39 ³⁴ per share in 2023. Adjusted EBITDA was $259,565,000 ³⁵ in 2025 compared to $102,774,000 ³⁶ in 2024 and negative $5,830,000 ³⁷ in 2023. Patient visits rose by 11.8% for the year ended December 31, 2025 compared to the same period in 2024. The company had $185,574,000 ³⁸ of cash and equivalents as of December 31, 2025 compared to $40,640,000 ³⁹ as of December 31, 2024.

The company expects to open four new hospital facilities in 2026. These facilities are either under construction or in advanced planning stages. The company anticipates launching one to three additional IPAs per year, principally in geographic areas around its existing micro-hospitals. There is no guarantee that any or all of the planned new hospitals or new IPAs will be successfully launched in the anticipated time frames.

The company's growth strategy is focused on expanding patient access to quality healthcare by broadening clinical services at existing facilities and by opening or acquiring new micro-hospital facilities in high demand areas of the United States. The company is also seeking to establish IPAs in many of the locales where it operates micro-hospitals in order to leverage its community presence and relationships with in-market physicians. The company currently has an IPA presence in the top three states for seniors: California, Florida, and Texas, which make up a quarter of the nation's seniors. To complement organic growth plans, the company may, in the normal course of business, consider and review opportunistic acquisitions.

The company's growth strategy also includes developing and operating innovative micro-hospitals, with plans to grow operations by expanding its innovative micro-hospital model into additional states and developing IPAs which leverage its presence and physician relationships in each community served. The company expects to open four new hospital facilities in 2026, which are either under construction or in advanced planning stages. The company anticipates launching one to three additional IPAs per year, principally in geographic areas around its existing micro-hospitals.

The company's operating expenses increased primarily due to revenue generated from the IDR process in addition to the opening of new facilities and volume growth. Contract services expense increased by $89.6 million primarily due to the cost associated with the IDR process. Payroll expense increased by $40.6 million due to the opening of two facilities in 2025 as well as due to the accrual of bonus payable in 2026. General and administrative costs increased $9.7 million attributed to increases in accrued bonus expense and payroll of $4.5 million, audit and audit-related fees associated with the restatement of 2024 financial statements of $2.3 million, recruiting fees of $1.4 million, and other professional and IT expenses of $1.4 million.

The company's growth plans include the development of new hospital locations. The company expects that in many of these locations it will lease facilities from newly established entities partially owned by related parties. The company routinely enters into equipment lease agreements to procure new or replacement equipment and may also finance these purchases with term debt. The company has smaller lines of credits available for working capital purposes and is presently working to supplement or replace these with larger financing commitments, which are subject to market conditions and may not be obtainable at favorable economic terms or at all.

Stock-based compensation expense for the years ended December 31, 2025, 2024, and 2023 was $117,003,000 ⁴⁰, $16,555,000 ⁴¹, and $2,836,000 ⁴², respectively. The company's stock-based compensation expense in the form of one-time obligations paid in common stock to qualifying under construction and ramping hospitals increased by $100.4 million. As of December 31, 2025, the company had approximately $20.0 million ⁴³ available under the Repurchase Program. In January 2026, subsequent to year end, the company repurchased the remaining shares available under the Repurchase Program for an aggregate purchase price of $20.0 million ⁴⁴, thereby completing the Repurchase Program. On March 4, 2026, subsequent to year end, the company announced that the Board authorized a second stock repurchase program of up to $25.0 million ⁴⁵ of the company's common stock.

Regulatory and litigation uncertainty under the No Surprises Act may reduce cash collections and increase dispute costs. Any significant changes to the federal arbitration process may result in a substantial decrease in the claim amounts the company will be able to recover in the future. In light of pending litigation before the Fifth Circuit referred to as TMA III, federal agencies have, in guidance issued on July 30, 2025, extended enforcement relief for services furnished before February 1, 2026, allowing insurers to continue to calculate in good faith the Qualified Payment Amount relying on previous methodologies, which can result in low QPAs and affect reimbursements received for out-of-network services and the outcome of IDR disputes. Updates to the Federal IDR portal have increased submission complexity and may delay dispute resolutions or require re-filings, raising administrative costs. The company is unable to predict the outcome of pending litigation, future legislative or regulatory changes, evolving arbitration practices, payor responses to ongoing enforcement of the NSA, and insurers' payment discipline.

The company's third party provider in the federal and state arbitration process, HaloMD, has been and may in the future be subject to lawsuits filed by health insurance providers, which may have an adverse impact on revenues, reputation, financial condition and the trading price of common stock. During the year ended December 31, 2025, HaloMD submitted approximately 50-60% of the company's medical claims through the IDR process. Pending or future litigation against HaloMD could materially adversely impact the revenues expected to be received from medical claims submitted on the company's behalf by HaloMD. The company has no contractual right to access or audit HaloMD's proprietary benchmarking data or documents prepared and submitted by HaloMD to the IDREs on behalf of the company.

Management's message emphasizes the company's mission to make exceptional concierge-level healthcare more accessible to people in the communities it serves, with a business strategy to increase stockholder value through earnings growth and cash flow generation. The strategic priorities emphasized for the period ahead include developing and operating innovative micro-hospitals, with plans to grow operations by expanding the micro-hospital model into additional states and developing IPAs which leverage the company's presence and physician relationships in each community served. Management also emphasizes providing a patient-centric care model, offering a differentiated provider engagement and partnership strategy where physician partners are co-investors and in many instances stockholders of Nutex, and having a scalable go-to-market strategy with centralized administrative support functions. The company expects to open four new hospital facilities in 2026 and anticipates launching one to three additional IPAs per year, principally in geographic areas around its existing micro-hospitals.

Total revenue for the year ended December 31, 2025 was $875,257,000 ⁵⁰ compared to $479,949,000 ⁵¹ in 2024. Net income attributable to Nutex Health Inc. was $70,789,000 ⁵² in 2025 compared to $52,097,000 ⁵³ in 2024. Diluted earnings per share was $10.48 ⁵⁴ in 2025 compared to $9.69 ⁵⁵ in 2024. Operating income was $275,625,000 ⁵⁶ in 2025 compared to $130,698,000 ⁵⁷ in 2024. Income tax expense was $64,424,000 ⁵⁸ in 2025 compared to $15,020,000 ⁵⁹ in 2024. Cash and cash equivalents were $185,574,000 ⁶⁰ as of December 31, 2025 compared to $40,640,000 ⁶¹ as of December 31, 2024. Adjusted EBITDA was $259,565,000 ⁶² in 2025 compared to $102,774,000 ⁶³ in 2024. Hospital division revenue was $844,162,000 ⁶⁴ in 2025 compared to $449,064,000 ⁶⁵ in 2024, and hospital division operating income was $444,027,000 ⁶⁶ in 2025 compared to $195,539,000 ⁶⁷ in 2024. Population health management division revenue was $31,095,000 ⁶⁸ in 2025 compared to $30,885,000 ⁶⁹ in 2024. Stock-based compensation expense was $117,003,000 ⁷⁰ in 2025 compared to $16,555,000 ⁷¹ in 2024. Interest expense was $22,226,000 ⁷² in 2025 compared to $19,932,000 ⁷³ in 2024.

Regulatory and litigation uncertainty under the No Surprises Act may reduce cash collections and increase dispute costs, with total accrued arbitration expenses of $49.7 million ⁴⁶ as of December 31, 2025 and $47.7 million ⁴⁷ as of December 31, 2024. The company's third-party provider in the arbitration process, HaloMD, submitted approximately 50-60% of the company's medical claims through the IDR process during 2025 and has been subject to lawsuits by health insurance providers, which could materially adversely impact revenues. The company's obligation to issue additional shares of common stock to former doctor owners of under construction hospitals may cause significant dilution, with an aggregate of 1,361,861 ⁴⁸ shares issued for seven hospitals with Measurement Periods ended on or prior to December 31, 2025, representing approximately 19.2% of outstanding shares as of December 31, 2025, and an estimated approximately 88,500 ⁴⁹ additional shares for three hospitals with Measurement Periods expiring on or prior to December 31, 2026, or 1.2% of outstanding shares as of December 31, 2025. The company's current business plans require a significant amount of capital, and if unable to generate sufficient cash from operations, borrow money on commercially reasonable terms, or sell equity at reasonable values, the company may not be able to execute its business plans. The company experienced operating losses in 2023 and could incur operating losses in the future as it implements its business plans.